Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 133-146

  Van Der Meer, A Franciscus ^a   Marcus, Marco A E ^a   Touw, Daniël J ^b   Proost, Johannes H ^c   Neef, Cees ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Apotheek Haagse Ziekenhuizen   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

maximum a posteriori Bayesian estimation; multiple regression analysis; optimal sampling strategy development

Indexed keywords

ALPHA INTERFERON; AMIKACIN; BLOOD CLOTTING FACTOR 8; BUSULFAN; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; CYCLOSPORIN; ENOXAPARIN; EPIGALLOCATECHIN GALLATE; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IBUPROFEN; INDISULAM; INULIN; LINEZOLID; METHOTREXATE; MIDAZOLAM; MIZORIBINE; MYCOPHENOLIC ACID; NAVELBINE; NEDAPLATIN; RAPAMYCIN; RUBITECAN; SABARUBICIN; TACROLIMUS; TEMOZOLOMIDE; TOPOTECAN; UNINDEXED DRUG;

BAYES THEOREM; INTERMETHOD COMPARISON; MAXIMUM A POSTERIORI BAYESIAN ESTIMATION; METHODOLOGY; MULTIPLE REGRESSION; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SAMPLING; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 79953190002     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820f40f8     Document Type: Review

References (98)

1. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem. 1991;37:1905-1908. (Pubitemid 121000142)
2. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens. 2002;11:619-626. (Pubitemid 35440843)
3. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens. 2002;11:657-663. (Pubitemid 35440849)
4. Rousseau A, Marquet P, Debord J, et al. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet. 2000;38: 315-353. (Pubitemid 30229470)
5. van Lent-Evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999; 21:63-73. (Pubitemid 29077456)
6. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172. (Pubitemid 351521643)
7. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276. (Pubitemid 351991390)
8. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2001;52(Suppl 1):45S-54S. (Pubitemid 32823031)
9. Campbell TJ,Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol. 2001;52(Suppl 1):21S-34S. (Pubitemid 32823029)
10. Meyer MM, Munar M, Udeaja J, et al. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol. 1993; 4:1306-1315.
11. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447. (Pubitemid 41623408)
12. Langers P, Press RR, den Hartigh J, et al. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration. Ther Drug Monit. 2008;30:456-461.
13. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(Suppl):S420-S425.
14. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005;44:1317-1328. (Pubitemid 41832572)
15. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit. 2003;25:28-35. (Pubitemid 36139822)
16. Langers P, Cremers SC, den Hartigh J, et al. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation. Aliment Pharmacol Ther. 2005;21:549-557. (Pubitemid 40381506)
17. Cyclosporine microemulsion (Neoral) absorption profiling and sparsesample predictors during the first 3 months after renal transplantation. Am J Transplant. 2002;2:148-156.
18. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486. (Pubitemid 34857899)
19. Pons G, Treluyer JM, Dimet J, et al. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit. 2002;24:9-14. (Pubitemid 34106724)
20. Panetta JC, Iacono LC, Adamson PC, et al. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res. 2003;9:5068-5077. (Pubitemid 37413554)
21. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5:411-459.
22. Proost JH, Eleveld DJ. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res. 2006;23:2748-2759. (Pubitemid 44885363)
23. Willemze AJ, Cremers SC, Schoemaker RC, et al. Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol. 2008;66: 539-545.
24. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007;29:96-102. (Pubitemid 46279882)
25. Langers P, Cremers SC, den Hartigh J, et al. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice. Aliment Pharmacol Ther. 2007;26:1447-1454. (Pubitemid 350045606)
26. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45:905-922. (Pubitemid 44299827)
27. Tokui K, Kimata T, Uchida K, et al. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics- based analysis in kidney transplant patients. Ther Drug Monit. 2004; 26:287-294. (Pubitemid 38703016)
28. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23-30. (Pubitemid 38140906)
29. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol. 2003;58:813-820. (Pubitemid 36577812)
30. Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas- kidney transplant recipients. Nephrol Dial Transplant. 2003;18: 1201-1208. (Pubitemid 36722525)
31. Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet. 2002;41:71-80. (Pubitemid 34158089)
32. Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit. 2005;27:378-388. (Pubitemid 40770997)
33. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27: 354-361. (Pubitemid 40770993)
34. Zahr N, Amoura Z, Debord J, et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet. 2008;47:277-284. (Pubitemid 351367437)
35. Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet. 2009;48:745-758.
36. de Winter BC, Neumann I, van Hest RM, et al. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit. 2009;31: 382-390.
37. Zhao W, Elie V, Baudouin V, et al. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol. 2010;69:358-366.
38. Saint-Marcoux F, Royer B, Debord J, et al. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet. 2009;48:667-675.
39. Huitema AD, Mathot RA, Tibben MM, et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther. 2000;67:621-630. (Pubitemid 30416078)
40. Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer. 2000;36:264-269. (Pubitemid 30102205)
41. Doz F, Urien S, Chatelut E, et al. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children. Cancer Chemother Pharmacol. 1998;42:250-254. (Pubitemid 28329203)
42. Panetta JC, Wilkinson M, Pui CH, et al. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn. 2002;29:171-188.
43. Tranchand B, Amsellem C, Chatelut E, et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 1999;43:316-322. (Pubitemid 29075889)
44. Perdaems N, Bachaud JM, Rouzaud P, et al. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur J Clin Pharmacol. 1998;54:677-683. (Pubitemid 29024197)
45. Plard C, Bressolle F, Fakhoury M, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;60:609-620. (Pubitemid 47084260)
46. Rousseau A, Sabot C, Delepine N, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet. 2002;41:1095-1104. (Pubitemid 35246783)
47. Min Y, Qiang F, Peng L, et al. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos. 2009;30:437-447.
48. Faltaos DW, Hulot JS, Urien S, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 2006;58:626-633. (Pubitemid 44167388)
49. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48:805-816.
50. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010; 49:683-692.
51. Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010; 32:129-135.
52. Nguyen L, Tranchand B, Puozzo C, et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol. 2002;53:459-468. (Pubitemid 34526497)
53. Sabot C, Marquet P, Debord J, et al. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol. 1998;54:171-175. (Pubitemid 28204273)
54. Gauvin A, Pinguet F, Culine S, et al. A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs. 2002;13: 473-480. (Pubitemid 34621051)
55. Bullock JM, Smith PF, Booker BM, et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 2006;28:62-66. (Pubitemid 44391695)
56. Salinger DH, Vicini P, Blough DK, et al. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol. 2010;50: 1292-1300.
57. Nguyen L, Leger F, Lennon S, et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57:191-198. (Pubitemid 41779838)
58. Payen S, Serreau R, Munck A, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003;47:3170-3178. (Pubitemid 37229575)
59. Overholser BR, Brophy DF, Sowinski KM. Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease. Ther Drug Monit. 2006;28:807-812. (Pubitemid 44967662)
60. Ralph LD, Thomson AH, Dobbs NA, et al. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling. Br J Clin Pharmacol. 2004;57:764-772. (Pubitemid 38748044)
61. Bolon-Larger M, Chamouard V, Bressolle F, et al. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit. 2007;29:20-26. (Pubitemid 46279872)
62. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010;16:597-605.
63. Beringer P, Aminimanizani A, Synold T, et al. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit. 2002;24:315-321. (Pubitemid 34246560)
64. Chatelut E, Rostaing L, Gregoire N, et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol. 1999; 47:365-371. (Pubitemid 29161267)
65. van Rossum LK, Mathot RA, Cransberg K, et al. Optimal sampling strategies to assess inulin clearance in children by the inulin singleinjection method. Clin Chem. 2003;49:1170-1179. (Pubitemid 36751105)
66. Poujol S, Pinguet F, Ychou M, et al. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol Rep. 2007;18:1613-1321.
67. Bolon M, Bastien O, Flamens C, et al. Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a Bayesian pharmacokinetic software (PKS) according to sparse sampling approach. J Pharm Pharmacol. 2003;55:765-771. (Pubitemid 36752720)
68. Ishibashi T, Fukumura K, Yano Y, et al. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Anticancer Res. 2005;25:1283-1289. (Pubitemid 40546803)
69. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 2006;45:1135-1148. (Pubitemid 44631392)
70. Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol. 2000;46:375-381.
71. Turner PK, Iacono LC, Panetta JC, et al. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemother Pharmacol. 2006;57:475-482. (Pubitemid 43087590)
72. Leger F, Loos WJ, Fourcade J, et al. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer. 2004;90: 343-347. (Pubitemid 38250626)
73. Foster DR, Sowinski KM, Chow HH, et al. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions. Ther Drug Monit. 2007;29:835-842. (Pubitemid 350190863)
74. Delattre IK, Musuamba FT, Nyberg J, et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010; 32:749-756.
75. Ishida K, Kaneda H, Uemura O, et al. Evaluation of limited sampling designs to estimate maximal concentration and area under the curve of mizoribine in pediatric patients with renal disease. Drug Metab Pharmacokinet. 2010 Oct 22 [Epub ahead of print].
76. Alffenaar JW, Kosterink JG, van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010;32:97-101.
77. Royer B, Jullien V, Guardiola E, et al. Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment. Clin Pharmacokinet. 2009;48:169-180.
78. Salinger DH, Blough DK, Vicini P, et al. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin Cancer Res. 2009;15:5280-5287.
79. Kirstein MN, Panetta JC, Gajjar A, et al. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemother Pharmacol. 2005;55:433-438. (Pubitemid 40568972)
80. van Rij CM, Huitema AD, Swart EL, et al. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol. 2005;60:477-485. (Pubitemid 41532447)
81. Schoemaker NE, Mathot RA, Schoffski P, et al. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemother Pharmacol. 2002; 50:514-517. (Pubitemid 35435532)
82. Colnot DR, Wilhelm AJ, Cloos J, et al. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy. J Nucl Med. 2001;42:1364-1367. (Pubitemid 32852612)
83. Mahmood I. A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am J Ther. 2003;10:88-92.
84. de Jonge ME, Huitema AD, Rodenhuis S, et al. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC). Ther Drug Monit. 2005;27: 393-402. (Pubitemid 40770999)
85. van Kesteren C, Mathot RA, Raymond E, et al. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1, 4-benzenedisulphonamide) . Br J Clin Pharmacol. 2002;54:463-471. (Pubitemid 35356871)
86. van Kesteren C, Mathjt RA, Lopez-Lazaro L, et al. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemother Pharmacol. 2001;48:459-466. (Pubitemid 33139867)
87. Royer B, Yin W, Pegram M, et al. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer. 2010;102:827-832.
88. Bos AM, Boom K, Vinks AA, et al. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755. Cancer Chemother Pharmacol. 2004;54:64-70. (Pubitemid 38858367)
89. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9:739-756. (Pubitemid 12184821)
90. Girard P, Mentré F. A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2005.
91. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45:365-383.
92. Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and 'multiple model' design of dosage regimens. Ther Drug Monit. 2000;22:346-353. (Pubitemid 30346453)
93. Dokoumetzidis A, Aarons L. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty. J Biopharm Stat. 2007;17: 851-867. (Pubitemid 47450740)
94. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
95. Proost JH. Validation of limited sampling models (LSM) for estimating AUC in therapeutic drug monitoring-is a separate validation group required? Int J Clin Pharmacol Ther. 2007;45:402-409. (Pubitemid 47045483)
96. Pattar R, Ensom MH. Utility of limited sampling strategies for anticancer agents in the clinical arena: a systematic review. Current Cancer Therapy Reviews. 2009;5:45-66.
97. Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46:471-494. (Pubitemid 46827857)
98. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.